Loading clinical trials...

Evaluate the Effect of Omalizumab on Markers of Asthma Impairment in Patients With Persistent Allergic Asthma | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDPhase 4NCT00870584

Evaluate the Effect of Omalizumab on Markers of Asthma Impairment in Patients With Persistent Allergic Asthma

This study will evaluate the effect of omalizumab on markers of impairment in patients with inadequately controlled persistent allergic asthma on Step 4 or above therapy as defined in the 2007 Nationa...

Lead sponsor: Novartis Pharmaceuticals•50 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Start Free Trial

Related studies

COMPLETEDPhase 3

Omalizumab in Patients With Moderate to Severe Persistent Allergic Asthma Not Adequately Controlled Despite GINA (2009) Step 4 Therapy

NCT01202903 · Persistent Allergic Asthma

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: November 17, 2011Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE4

Enrollment271

Start dateMar 2009

Last updatedNov 17, 2011

Condition

Persistent Allergic Asthma

Locations shown

Jasper Summit Research, LLC

Jasper, Alabama

Allergy Asthma and Immunology Center of Alaska

Anchorage, Alaska

Medical Research of Arizona, A division of Allergy Asthma & Immunology Associates, LTD

Scottsdale, Arizona

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 17, 2011Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions